Adamis Pharmaceuticals Corporation (ADMP): Price and Financial Metrics

Adamis Pharmaceuticals Corporation (ADMP): $0.59

0.00 (-0.53%)

POWR Rating

Component Grades














  • Growth is the dimension where ADMP ranks best; there it ranks ahead of 61.21% of US stocks.
  • The strongest trend for ADMP is in Quality, which has been heading up over the past 169 days.
  • ADMP ranks lowest in Quality; there it ranks in the 3rd percentile.

ADMP Stock Summary

  • The ratio of debt to operating expenses for Adamis Pharmaceuticals Corp is higher than it is for about just 6.52% of US stocks.
  • With a year-over-year growth in debt of -80.35%, Adamis Pharmaceuticals Corp's debt growth rate surpasses only 3.62% of about US stocks.
  • As for revenue growth, note that ADMP's revenue has grown -42.77% over the past 12 months; that beats the revenue growth of just 4.25% of US companies in our set.
  • Stocks that are quantitatively similar to ADMP, based on their financial statements, market capitalization, and price volatility, are QUMU, CPSI, KERN, SANW, and IBIO.
  • Visit ADMP's SEC page to see the company's official filings. To visit the company's web site, go to

ADMP Valuation Summary

  • ADMP's price/sales ratio is 9.8; this is 13.66% lower than that of the median Healthcare stock.
  • Over the past 243 months, ADMP's price/sales ratio has gone down 86.8.
  • ADMP's price/earnings ratio has moved up 3.4 over the prior 243 months.

Below are key valuation metrics over time for ADMP.

Stock Date P/S P/B P/E EV/EBIT
ADMP 2021-08-31 9.8 46.4 -3.3 -3.3
ADMP 2021-08-30 9.5 44.7 -3.2 -3.2
ADMP 2021-08-27 9.8 46.4 -3.3 -3.3
ADMP 2021-08-26 9.7 46.0 -3.3 -3.3
ADMP 2021-08-25 10.0 47.3 -3.3 -3.4
ADMP 2021-08-24 10.2 48.1 -3.4 -3.4

ADMP Growth Metrics

    Its year over year revenue growth rate is now at -42.77%.
  • The year over year cash and equivalents growth rate now stands at 173.77%.
  • The 2 year price growth rate now stands at -85.1%.
ADMP's revenue has moved down $9,596,739 over the prior 21 months.

The table below shows ADMP's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 12.51713 -36.52327 -57.42382
2020-12-31 16.5274 -20.90136 -49.39109
2020-09-30 18.43029 -18.42784 -34.70541
2020-06-30 20.03275 -16.57601 -34.21996
2020-03-31 21.87131 -15.85191 -30.69283
2019-12-31 22.11387 -19.88567 -29.30677

ADMP's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ADMP has a Quality Grade of F, ranking ahead of 1.65% of graded US stocks.
  • ADMP's asset turnover comes in at 0.414 -- ranking 112th of 682 Pharmaceutical Products stocks.
  • ELTP, XENE, and LPTX are the stocks whose asset turnover ratios are most correlated with ADMP.

The table below shows ADMP's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2020-12-31 0.414 0.099 -4.946
2020-09-30 0.417 0.120 -2.753
2020-06-30 0.432 0.173 -2.533
2020-03-31 0.453 0.289 -2.096
2019-12-31 0.441 0.300 -1.898
2019-09-30 0.393 0.309 -2.593

ADMP Price Target

For more insight on analysts targets of ADMP, see our ADMP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $1.25 Average Broker Recommendation 2 (Hold)

ADMP Stock Price Chart Interactive Chart >

Price chart for ADMP

ADMP Price/Volume Stats

Current price $0.59 52-week high $1.74
Prev. close $0.59 52-week low $0.55
Day low $0.57 Volume 1,488,014
Day high $0.62 Avg. volume 3,537,758
50-day MA $0.68 Dividend yield N/A
200-day MA $0.91 Market Cap 87.38M

Adamis Pharmaceuticals Corporation (ADMP) Company Bio

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, engages in developing and commercializing products in the therapeutic areas of allergy and respiratory disease. The company is based in San Diego, California.

ADMP Latest News Stream

Event/Time News Detail
Loading, please wait...

ADMP Latest Social Stream

Loading social stream, please wait...

View Full ADMP Social Stream

Latest ADMP News From Around the Web

Below are the latest news stories about Adamis Pharmaceuticals Corp that investors may wish to consider to help them evaluate ADMP as an investment opportunity.

Adamis Pharma Updates 1 Key Risk Factor

3 clinical trial in patients affected by COVID-19. Importantly, Tempol has demonstrated antiviral, anti-inflammatory, and antioxidant activity. While there have been recent approvals for oral antiviral drugs, Adamis noted Tempol’s unique mechanism of action and safety profile would offer an unmet medical requirement. With this development in mind, let us take a look at the changes in Adamis’ key risk factors that investors should know.

Kailas Salunkhe on TipRanks | January 12, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Grab a cup of coffee and get ready for another busy day of trading as we start with the biggest pre-market stock movers for Tuesday!

William White on InvestorPlace | January 11, 2022

Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19

SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration (FDA) for Tempol for the treatment and prevention of COVID-19. Tempol is currently being studied in a Phase 2/3 clinical trial in adult patients with confirmed COVID-19 infection. Tempol has been shown to have antiviral, anti-inflammatory, and antioxidant activity. Although recent oral antiviral drugs ha

Yahoo | January 10, 2022

Is the Options Market Predicting a Spike in Adamis Pharmaceuticals (ADMP) Stock?

Investors need to pay close attention to Adamis Pharmaceuticals (ADMP) stock based on the movements in the options market lately.

Yahoo | December 20, 2021

Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI™

Drug overdoses are the leading cause of death for those under age 50SAN DIEGO, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that additional data in a quantitative systems pharmacology model supports the dose of naloxone hydrochloride that is included in the company’s ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL product. The model data supports the dose of naloxone in ZIMHI as being more likely to produce successful resuscitation of high

Yahoo | December 1, 2021

Read More 'ADMP' Stories Here

ADMP Price Returns

1-mo 2.90%
3-mo -43.81%
6-mo -50.00%
1-year -57.86%
3-year -81.15%
5-year -81.27%
YTD -2.48%
2021 24.72%
2020 -30.74%
2019 -68.87%
2018 -48.86%
2017 39.68%

Continue Researching ADMP

Here are a few links from around the web to help you further your research on Adamis Pharmaceuticals Corp's stock as an investment opportunity:

Adamis Pharmaceuticals Corp (ADMP) Stock Price | Nasdaq
Adamis Pharmaceuticals Corp (ADMP) Stock Quote, History and News - Yahoo Finance
Adamis Pharmaceuticals Corp (ADMP) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9517 seconds.